Cargando…
Targeting the “undruggable” RAS - new strategies - new hope?
K-RAS is the most frequently mutated oncogene in solid tumors, such as pancreatic, colon or lung cancer. The GTPase K-RAS can either be in an active (GTP-loaded) or inactive (GDP-loaded) form. In its active form K-RAS forwards signals from growth factors, cytokines or hormones to the nucleus, regula...
Autores principales: | Mörchen, Britta, Shkura, Oleksandr, Stoll, Raphael, Helfrich, Iris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992515/ https://www.ncbi.nlm.nih.gov/pubmed/35582595 http://dx.doi.org/10.20517/cdr.2019.21 |
Ejemplares similares
-
Sequence‐Selective Covalent CaaX‐Box Receptors Prevent Farnesylation of Oncogenic Ras Proteins and Impact MAPK/PI3 K Signaling
por: Franz, Matthias, et al.
Publicado: (2021) -
Targeting the undruggable oncogenic KRAS: the dawn of hope
por: Asimgil, Hande, et al.
Publicado: (2022) -
Drugging the Undruggable: Advances on RAS Targeting in Cancer
por: Molina-Arcas, Miriam, et al.
Publicado: (2021) -
Allosteric Activation of GDP-Bound Ras Isoforms by Bisphenol Derivative Plasticisers
por: Schöpel, Miriam, et al.
Publicado: (2018) -
Therapeutic targeting of “undruggable” MYC
por: Llombart, Victor, et al.
Publicado: (2021)